The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013
Open accessAbstract
IMPORTANCE: Carbapenem-resistant Enterobacteriaceae (CRE) are increasingly reported worldwide as a cause of infections with high-mortality rates. Assessment of the US epidemiology of CRE is needed to inform national prevention efforts. OBJECTIVE: To determine the population-based CRE incidence and describe the characteristics and resistance mechanism associated with isolates from 7 US geographical areas. DESIGN, SETTING, AND PARTICIPANTS: Population- and laboratory-based active surveillance of CRE conducted among individuals living in 1 of 7 US metropolitan areas in Colorado, Georgia, Maryland, Minnesota, New Mexico, New York, and Oregon. Cases of CRE were defined as carbapenem-nonsusceptible (excluding ertapenem) and extended-spectrum cephalosporin-resistant Escherichia coli, Enterobacter aerogenes, Enterobacter cloacae complex, Klebsiella pneumoniae, or Klebsiella oxytoca that were recovered from sterile-site or urine cultures during 2012-2013. Case records were reviewed and molecular typing for common carbapenemases was performed. EXPOSURES: Demographics, comorbidities, health care exposures, and culture source and location. MAIN OUTCOMES AND MEASURES: Population-based CRE incidence, site-specific standardized incidence ratios (adjusted for age and race), and clinical and microbiological characteristics. RESULTS: Among 599 CRE cases in 481 individuals, 520 (86.8%; 95% CI, 84.1%-89.5%) were isolated from urine and 68 (11.4%; 95% CI, 8.8%-13.9%) from blood. The median age was 66 years (95% CI, 62.1-65.4 years) and 284 (59.0%; 95% CI, 54.6%-63.5%) were female. The overall annual CRE incidence rate per 100<000 population was 2.93 (95% CI, 2.65-3.23). The CRE standardized incidence ratio was significantly higher than predicted for the sites in Georgia (1.65 [95% CI, 1.20-2.25]; P < .001), Maryland (1.44 [95% CI, 1.06-1.96]; P = .001), and New York (1.42 [95% CI, 1.05-1.92]; P = .048), and significantly lower than predicted for the sites in Colorado (0.53 [95% CI, 0.39-0.71]; P < .001), New Mexico (0.41 [95% CI, 0.30-0.55]; P = .01), and Oregon (0.28 [95% CI, 0.21-0.38]; P < .001). Most cases occurred in individuals with prior hospitalizations (399/531 [75.1%; 95% CI, 71.4%-78.8%]) or indwelling devices (382/525 [72.8%; 95% CI, 68.9%-76.6%]); 180 of 322 (55.9%; 95% CI, 50.0%-60.8%) admitted cases resulted in a discharge to a long-term care setting. Death occurred in 51 (9.0%; 95% CI, 6.6%-11.4%) cases, including in 25 of 91 cases (27.5%; 95% CI, 18.1%-36.8%) with CRE isolated from normally sterile sites. Of 188 isolates tested, 90 (47.9%; 95% CI, 40.6%-55.1%) produced a carbapenemase. CONCLUSIONS AND RELEVANCE: In this population- and laboratory-based active surveillance system in 7 states, the incidence of CRE was 2.93 per 100<000 population. Most CRE cases were isolated from a urine source, and were associated with high prevalence of prior hospitalizations or indwelling devices, and discharge to long-term care settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Burden of Clostridium difficile Infection in the United States
Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408913 · Cited by 2,641
Self-citationPerformance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement
Cockerill, F. R., & Clinical (2008) · Medical Entomology and Zoology · Cited by 2,065
The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria
Nordmann, P., Cuzon, G., & Naas, T. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70054-4 · Cited by 1,579
Carbapenem-Resistant Enterobacteriaceae: Epidemiology and Prevention
Gupta, N., Limbago, B. M., Patel, J. B., & Kallen, A. J. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir202 · Cited by 1,033
Self-citationPatel, G., Huprikar, S., Factor, S. H., Jenkins, S. G., & Calfee, D. P. (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/592412 · Cited by 836
Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community
Pitout, J. D. D., Nordmann, P., Laupland, K. B., & Poirel, L. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki166 · Cited by 790
Vital signs: carbapenem-resistant Enterobacteriaceae.
(2013) · PubMed Central · Cited by 603
Dantes, R. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.10423 · Cited by 452
Cleveland, A. A., Farley, M. M., Harrison, L. H., Stein, B., Hollick, R., Lockhart, S. R., Magill, S. S., Derado, G., Park, B. J., & Chiller, T. M. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis697 · Cited by 366
Surveillance Definitions of Infections in Long-Term Care Facilities: Revisiting the McGeer Criteria
Stone, N. D., Ashraf, M. S., Calder, J., Crnich, C. J., Crossley, K., Drinka, P. J., Gould, C. V., Juthani-Mehta, M., Lautenbach, E., Loeb, M., et al. (2012) · Infection Control & Hospital Epidemiology · doi:10.1086/667743 · Cited by 322
Doi, Y., Park, Y. S., Rivera, J. I., Adams-Haduch, J. M., Hingwe, A., Sordillo, E. M., Lewis, J. S., Howard, W. J., Johnson, L. E., Polsky, B., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cis942 · Cited by 303
Won, S. Y., Munoz-Price, L. S., Lolans, K., Hota, B., Weinstein, R. A., Hayden, M. K., & Program, F. T. C. F. D. C. A. P. E. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir482 · Cited by 240
Lin, M. Y., Lyles-Banks, R. D., Lolans, K., Hines, D. W., Spear, J. B., Petrak, R., Trick, W. E., Weinstein, R. A., Hayden, M. K., Acuna, N., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit500 · Cited by 226
New Delhi Metallo-β-Lactamase–producingEnterobacteriaceae, United States
Rasheed, J. K., Kitchel, B., Zhu, W., Anderson, K. F., Clark, N. C., Ferraro, M. J., Savard, P., Humphries, R. M., Kallen, A. J., & Limbago, B. M. (2013) · Emerging infectious diseases · doi:10.3201/eid1906.121515 · Cited by 169
Self-citationElemam, A., Rahimian, J., & Mandell, W. (2009) · Clinical Infectious Diseases · doi:10.1086/600042 · Cited by 156
Epidemiology and prevention of carbapenem-resistant Enterobacteriaceae in the United States
Guh, A. Y., Limbago, B. M., & Kallen, A. J. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.902306 · Cited by 111
Self-citationPrabaker, K. K., Lin, M. Y., McNally, M., Cherabuddi, K., Ahmed, S. S., Norris, A., Lolans, K., Odeh, R. M., Chundi, V. V., Weinstein, R. A., et al. (2012) · Infection Control and Hospital Epidemiology · doi:10.1086/668435 · Cited by 99
Banerjee, R., Strahilevitz, J., Johnson, J. R., Nagwekar, P. P., Schora, D. M., Shevrin, I., Du, H., Peterson, L. R., & Robicsek, A. A. (2013) · Infection Control and Hospital Epidemiology · doi:10.1086/671725 · Cited by 63
Rodríguez‐Baño, J., Alcalá, J., Cisneros, J. M., Grill, F., Oliver, A., Horcajada, J. P., Tórtola, T., Mirelis, B., Navarro, G., Cuenca, M., et al. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp028 · Cited by 30
Reno, J., Schenck, C., Scott, J., Clark, L. A., Wang, Y. F., Ray, S. M., Vagnone, P. S., & Jacob, J. T. (2014) · Infection Control and Hospital Epidemiology · doi:10.1086/675608 · Cited by 12
Self-citation
Cited by
Antimicrobial Resistance in ESKAPE Pathogens
De Oliveira, D. M. P., Forde, B. M., Kidd, T. J., Harris, P. N. A., Schembri, M. A., Beatson, S. A., Paterson, D. L., & Walker, M. J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00181-19 · Cited by 2,078
Klebsiella pneumoniae: Going on the Offense with a Strong Defense
Paczosa, M. K., & Mecsas, J. (2016) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00078-15 · Cited by 1,988
Logan, L. K., & Weinstein, R. A. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw282 · Cited by 1,584
The global epidemiology of carbapenemase-producing Enterobacteriaceae
van Duin, D., & Doi, Y. (2017) · Virulence · doi:10.1080/21505594.2016.1222343 · Cited by 1,004
Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria
Nordmann, P., & Poirel, L. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz824 · Cited by 721
Metadata
- Authors
- Guh, A. Y., Bulens, S. N., Mu, Y., Jacob, J. T., Reno, J., Scott, J., Wilson, L. E., Vaeth, E., Lynfield, R., Shaw, K. M., Vagnone, P. M. S., Bamberg, W. M., Janelle, S. J., Dumyati, G., Concannon, C., Beldavs, Z., Cunningham, M., Cassidy, P. M., Phipps, E. C., Kenslow, N., Travis, T., Lonsway, D., Rasheed, J. K., Limbago, B. M., & Kallen, A. J.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2015-10-13
- Volume
- 314
- Issue
- 14
- Pages
- 1479
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2107530240
- Cited by
- 369
- References
- 20
- FWCI
- 13.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.